ArticleCurrent behavioral neuroscience reports2018
Rapid-Acting Antidepressants: Mechanistic Insights and Future Directions.
Article in Current behavioral neuroscience reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry.Pharmacopsychiatry · 2022Pooled it
- Trial
- Exploring the Potential of Coumarin Derivatives on Serotonin Receptors 5-HTInternational journal of molecular sciences · 2025Article
- Design, synthesis, and biological evaluation of piperazine derivatives involved in the 5-HTJournal of enzyme inhibition and medicinal chemistry · 2024Article
- Analysis of medication rule of Traditional Chinese Medicine in treating depression based on data mining.Heliyon · 2024Article
- Ethical considerations in rapid and novel treatments in psychiatry.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Transcriptional signatures of early-life stress and antidepressant treatment efficacy.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Pharmacological evidence for glutamatergic pathway involvement in the antidepressant-like effects of 2-phenyl-3-(phenylselanyl)benzofuran in male Swiss mice.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Fasting produces antidepressant-like effects via activating mammalian target of rapamycin complex 1 signaling pathway in ovariectomized mice.Neural regeneration research · 2023Article
- Molecular basis and mechanism of action ofChinese herbal medicines · 2023Review
- Article
- The long noncoding RNA FEDORA is a cell type- and sex-specific regulator of depression.Science advances · 2022Article
- In VivoNeurochemical research · 2022Review
- 5q35 duplication presents with psychiatric and undergrowth phenotypes mediated by NSD1 overexpression and mTOR signaling downregulation.Human genetics · 2021Article
- Genetic and pharmacological inhibition of two-pore domain potassium channel TREK-1 alters depression-related behaviors and neuronal plasticity in the hippocampus in mice.CNS neuroscience & therapeutics · 2021Article
- Cumulative Stress Burden on Motivated Action Revealed.Biological psychiatry · 2020Article
- Crocin Reverses Depression-Like Behavior in Parkinson Disease Mice via VTA-mPFC Pathway.Molecular neurobiology · 2020Article
- GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions.The Journal of clinical investigation · 2020Article
- Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress.Behavioural brain research · 2020Review
- The Effect of Propofol on a Forced Swim Test in Mice at 24 Hours.Current therapeutic research, clinical and experimental · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewKetamine produces rapid (within hours) antidepressant actions, even in patients considered treatment resistant, and even shows promise for suicidal ideation. Here, we review current research on the molecular and cellular mechanisms of ketamine and other novel rapid-acting antidepressants, and briefly explore gender differences in the pathophysiology and treatment of MDD. RECENT
findingsKetamine, an NMDA receptor antagonist, increases BDNF release and synaptic connectivity, opposing the deficits caused by chronic stress and depression. Efforts are focused on the development of novel rapid agents that produce similar synaptic and rapid antidepressant actions, but without the side effects of ketamine. The impact of gender on the response to ketamine and other rapid-acting antidepressants is in early stages of investigation. SUMMARY: The discovery that ketamine produces rapid therapeutic actions for depression and suicidal ideation represents a major breakthrough and much needed alternative to currently available medications. However, novel fast acting agents with fewer side effects are needed, as well as elucidation of the efficacy of these rapid-acting antidepressants for depression in women.
Indexed as
Identifiers
30034992PMC6051539What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.